Top news from MedWatch this week

Miss anything?

BY MIKKEL AABENHUS HEMMINGSEN

Published: 08.07.22 at 15:17

More from MedWatch

ALK to exit Turkish market: "It's bad business if all we get is peanuts"

ALK's Turkish workforce will have look for employment elsewhere | Photo: ALK / PR

A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.

Genmab postpones crucial cancer candidate decision following Abbvie exit

For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.

Genmab says new arbitration builds on a straightforward question

”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.